GARDP : Monaco supports a major clinical trial to identify new treatments for newborns with severe infections

Published on 16 June 2025 at 12:00 - Modified the 16 June 2025 at 16:29

 

Antimicrobial resistance (AMR) is a major public health threat, particularly for the 3 million newborns worldwide who suffer from severe infections every year. Standard antibiotics are losing their effectiveness in the face of increasing resistance, leading to a large number of deaths among these children.

Since 2019, the Principality of Monaco, through the Government of Monaco's Department of International Cooperation, has been actively supporting a clinical research programme to identify new combination treatments to save the lives of newborns suffering from sepsis.

As part of its third support for the project, the Monegasque Cooperation is delighted to see the start of the second phase of this research, marked by the 1st recruitment of a newborn baby at Tygerberg Hospital in South Africa, as part of a cohort of 3,000 children aged between 0 and 28 days, expected by 2028.

The results obtained at the end of this second phase of research will be of vital importance in offering new treatment opportunities to these children and thus saving lives.